Biologic Therapies V:
Lessons Learned from the First Decade
Focusing on New Targets and Agents
Biologic agents have become an important part of the overall therapeutic care plan for patients with autoimmune and inflammatory disorders. During the last decade, new biologic therapeutics have been developed that are designed to specifically target aspects of the immune system (eg, T cells and B cells), cytokines (eg, tumor necrosis factor and interleukins), adhesion molecules, and various growth factors.
The Cleveland Clinic R.J. Fasenmyer Center for Clinical Immunology hosts the Biologic Therapies V Summit, an advanced course that brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics. From the course a highly successful online series is developed as a key online resource for comprehensive reviews and clinical analyses of biologic therapies.
The Biologic Therapies V: Lessons Learned from the First Decade Focusing on New Targets and Agents online series, an international, multi-disciplinary faculty of experts critically appraise recent basic laboratory breakthroughs in terms of their potential clinical implications and provide in-depth analyses of approved agents, new agents, predicting toxicity, clinical controversies, and new indications.
This activity has expired.
Please click on link to direct you to our Rheumatology/Immunology specialty section.